Johnson PW
Johnson PW
Professor of Medical Oncology, University of Southampton
Adresse e-mail validée de
Citée par
Citée par
Research methods for managers
J Gill, P Johnson
Sage, 2002
Rituximab (anti-CD20 monoclonal antibody) for the treatment of patients with relapsing or refractory aggressive lymphoma: a multicenter phase II study
B Coiffier, C Haioun, N Ketterer, A Engert, H Tilly, D Ma, P Johnson, ...
Blood, The Journal of the American Society of Hematology 92 (6), 1927-1932, 1998
Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma
ML Wang, S Rule, P Martin, A Goy, R Auer, BS Kahl, W Jurczak, ...
New England Journal of Medicine 369 (6), 507-516, 2013
European phase II study of rituximab (chimeric anti-CD20 monoclonal antibody) for patients with newly diagnosed mantle-cell lymphoma and previously treated mantle-cell lymphoma …
JM Foran, AZ Rohatiner, D Cunningham, RA Popescu, P Solal-Celigny, ...
Journal of Clinical Oncology 18 (2), 317-324, 2000
Diffuse large B-cell lymphoma (DLBCL): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up
H Tilly, M Gomes da Silva, U Vitolo, A Jack, M Meignan, ...
Annals of oncology 26 (suppl_5), v116-v125, 2015
Complement-mediated lysis by anti-CD20 mAb correlates with segregation into lipid rafts
MS Cragg, SM Morgan, HTC Chan, BP Morgan, AV Filatov, ...
Blood, The Journal of the American Society of Hematology 101 (3), 1045-1052, 2003
Clinical trials of antibody therapy
MJ Glennie, PWM Johnson
Immunology today 21 (8), 403-410, 2000
Results of a trial of PET-directed therapy for early-stage Hodgkin’s lymphoma
J Radford, T Illidge, N Counsell, B Hancock, R Pettengell, P Johnson, ...
New England Journal of Medicine 372 (17), 1598-1607, 2015
Rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisolone in patients with newly diagnosed diffuse large B-cell non-Hodgkin lymphoma: a phase 3 comparison of …
D Cunningham, EA Hawkes, A Jack, W Qian, P Smith, P Mouncey, ...
The Lancet 381 (9880), 1817-1826, 2013
Patterns of survival in patients with recurrent follicular lymphoma: a 20-year study from a single center.
PW Johnson, AZ Rohatiner, JS Whelan, CG Price, S Love, J Lim, ...
Journal of Clinical Oncology 13 (1), 140-147, 1995
Adapted treatment guided by interim PET-CT scan in advanced Hodgkin’s lymphoma
P Johnson, M Federico, A Kirkwood, A Fosså, L Berkahn, A Carella, ...
N Engl J Med 374, 2419-2429, 2016
First clinical use of ofatumumab, a novel fully human anti-CD20 monoclonal antibody in relapsed or refractory follicular lymphoma: results of a phase 1/2 trial
A Hagenbeek, O Gadeberg, P Johnson, L Møller Pedersen, J Walewski, ...
Blood, The Journal of the American Society of Hematology 111 (12), 5486-5495, 2008
The role of cognitive impairment in general functioning in major depression
BT Baune, R Miller, J McAfoose, M Johnson, F Quirk, D Mitchell
Psychiatry research 176 (2-3), 183-189, 2010
The mechanisms of action of rituximab in the elimination of tumor cells
P Johnson, M Glennie
Seminars in oncology 30 (1), 3-8, 2003
Antigenic modulation limits the efficacy of anti-CD20 antibodies: implications for antibody selection
SA Beers, RR French, HTC Chan, SH Lim, TC Jarrett, RM Vidal, ...
Blood, The Journal of the American Society of Hematology 115 (25), 5191-5201, 2010
Myeloablative therapy with autologous bone marrow transplantation as consolidation therapy for recurrent follicular lymphoma.
AZ Rohatiner, PW Johnson, CG Price, SJ Arnott, JA Amess, AJ Norton, ...
Journal of Clinical Oncology 12 (6), 1177-1184, 1994
Anti-CD20 monoclonal antibodies: historical and future perspectives
SH Lim, SA Beers, RR French, PWM Johnson, MJ Glennie, MS Cragg
haematologica 95 (1), 135-143, 2010
Concordance between four European centres of PET reporting criteria designed for use in multicentre trials in Hodgkin lymphoma
SF Barrington, W Qian, EJ Somer, A Franceschetto, B Bagni, E Brun, ...
European journal of nuclear medicine and molecular imaging 37 (10), 1824-1833, 2010
J Michels, PWM Johnson, G Packham
The international journal of biochemistry & cell biology 37 (2), 267-271, 2005
Antisense oligonucleotides suppress B-cell lymphoma growth in a SCID-hu mouse model.
FE Cotter, P Johnson, P Hall, C Pocock, JK Cowell, G Morgan
Oncogene 9 (10), 3049-3055, 1994
Le système ne peut pas réaliser cette opération maintenant. Veuillez réessayer plus tard.
Articles 1–20